Jane Street Group LLC Purchases 49,317 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Jane Street Group LLC raised its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 328.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,323 shares of the company's stock after buying an additional 49,317 shares during the quarter. Jane Street Group LLC owned about 0.25% of Eton Pharmaceuticals worth $857,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ETON. Baader Bank Aktiengesellschaft acquired a new position in shares of Eton Pharmaceuticals in the fourth quarter valued at $373,000. Raymond James Financial Inc. bought a new position in Eton Pharmaceuticals in the fourth quarter valued at about $147,000. Anchor Capital Advisors LLC bought a new position in Eton Pharmaceuticals in the fourth quarter valued at about $805,000. Barclays PLC bought a new position in Eton Pharmaceuticals during the fourth quarter worth about $731,000. Finally, JPMorgan Chase & Co. boosted its holdings in Eton Pharmaceuticals by 7,086.9% during the fourth quarter. JPMorgan Chase & Co. now owns 51,961 shares of the company's stock worth $692,000 after buying an additional 51,238 shares during the last quarter. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Price Performance

Shares of Eton Pharmaceuticals stock traded down $1.16 during midday trading on Thursday, reaching $18.92. The company had a trading volume of 969,366 shares, compared to its average volume of 202,585. The stock has a fifty day moving average price of $15.71 and a 200 day moving average price of $14.58. The firm has a market cap of $507.40 million, a PE ratio of -86.00 and a beta of 1.22. Eton Pharmaceuticals, Inc. has a fifty-two week low of $3.18 and a fifty-two week high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The company had revenue of $17.28 million during the quarter, compared to analyst estimates of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ETON. B. Riley reaffirmed a "buy" rating and set a $26.00 price target (up previously from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th. Craig Hallum increased their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Finally, HC Wainwright restated a "buy" rating and issued a $35.00 price target (up previously from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.